TBNHealth
STAT+: AbbVie skin disorder drug succeeds in late-stage trial, but results miss market expectations
Publication: STAT
Author: Jonathan Wosen
Source published: 22/10/2026, 18:22:27 UTC
Briefing created: 22/10/2026, 18:44:12 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 22/10/2026, 18:36:24 UTC.
Briefings
AbbVie's lutikizumab therapy achieved a 75% reduction in inflamed bumps versus 23.4% in the placebo group for hidradenitis suppurativa in the Phase 3 Intrepid trial, meeting eight secondary endpoints despite missing market expectations. The study enrolled 1,400 patients over 16 weeks, with adverse events showing nearly identical rates between groups. Experts remain doubtful the drug can compete with current standard care due to these results.
Key points
- In the Phase 3 Intrepid trial, 31.4% of patients receiving weekly lutikizumab injections achieved a 75% or greater reduction in inflamed bumps and abscesses compared to 23.4% in the placebo group after 16 weeks.
- The drug met eight secondary endpoints including improvements in skin pain and flares, while adverse event rates remained nearly identical between the treatment and placebo groups.
Context
AbbVie's lutikizumab therapy achieved a 75% reduction in inflamed bumps versus 23.4% in the placebo group for hidradenitis suppurativa in the Phase 3 Intrepid trial, meeting eight secondary endpoints including improvements in skin pain and flares. The drug was generally safe and well tolerated, with adverse event rates nearly identical between groups. Experts remain doubtful the drug can compete with current standard care due to these results.
Limitations
The evidence is limited to the Phase 3 Intrepid trial with 1,400 patients enrolled over 16 weeks. The study's primary endpoint was the 75% reduction in inflamed bumps, and while secondary endpoints were met, the drug missed market expectations. No additional background context is supplied beyond the trial details.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 22/10/2026, 18:44:12 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeielbtauwt6b2obovkt65kpierwzvbzd66xpkvqwy5ey5jqbl6i5du